Invest1 distinct publisher3 min readPublished
Rasonque roughly doubled median survival against a 6.7-month chemotherapy arm in a cancer where nearly every tumor carries a KRAS mutation. Neither condition repeats in the bigger indications.
The Investor · Invest desk
Compiled by The InvestorSomething wrong?How this is made
Pancreatic adenocarcinoma was the right disease to prove this mechanism and the wrong one to size it. KRAS is mutated in nearly all pancreatic cancers [12], which is why the label requires no test to identify a specific RAS mutation before prescribing [3]: the tumor type is the biomarker. The control arm was also about as low as regulated oncology gets, a median of 6.7 months on standard chemotherapy against 13.2 months on the drug, a gain of 6.5 months and just short of a doubling [4][1]. Adenocarcinoma accounts for 90% to 95% of pancreatic cases [11], so the enrolled population sits close to the whole disease.
In lung, colorectal and ovarian cancer, KRAS mutations turn up in many cases rather than nearly all [12]. That restores two things this trial never had to face: a diagnostic gate deciding who is eligible, and comparators that already deliver more than months. Revolution Medicines is running daraxonrasib through late-stage lung trials [13], and that is where the druggability claim meets a harder arithmetic.
The pricing works the same way. At $39,800 per 30-day supply [6], list cost is roughly $484,000 a year [3] and about $525,000 across the 13.2-month median [2]. In this indication, mortality is the cost control. Five-year survival has sat at 13% for three years while all cancers combined reached 70% [9], a 57-point gap [6], and about 80% of patients are metastatic at diagnosis, roughly 54,000 of the 67,530 Americans expected to be diagnosed in 2026 [8][10][5]. In a cancer patients survive for years, the same monthly price compounds, and that is the conversation payers will actually have.
The platform framing deserves precise attribution. The claim that RAS mutations appear in roughly a quarter of all human cancers, and that Revolution has built a platform rather than a drug, comes from Danish Nagda, an early shareholder who told Fortune he has been "very, very bullish" on the stock [2][18]. The clinical read is separate: Brian Wolpin, the trial's principal investigator at Dana-Farber, said the approval gives physicians confidence that directly inhibiting RAS can make a striking difference for patients [16], and Anna Berkenblit of the Pancreatic Cancer Action Network called it the most significant advance yet in the disease [17].
On the review timeline, the Fortune account argues with itself: it reports the decision landed 6.5 months before the user-fee deadline, then says the figure is unverified and that the Breakthrough Therapy and Orphan Drug designations plus the National Priority Voucher pilot explain the compressed schedule without it [14][15]. What is documented is narrower than the headline number. The revenue base is similarly unresolved. An expanded access program opened in May has already reached more than 2,000 patients [7], and eligible insured patients may pay as little as $0 through the company's support program [6], so the list price tells you very little about net.
Ranked by verification strength, evidence, and original report placement.
RAS mutations drive tumor growth in most pancreatic cancers and in roughly a quarter of all human cancers overall; the quarter figure was stated by early Revolution shareholder Dr. Danish Nagda.
The drug targets a KRAS gene mutation found in nearly all pancreatic cancers and in many cases of lung, colorectal and ovarian cancer.
The FDA on Wednesday approved Rasonque, a once-daily pill developed by Revolution Medicines to block several forms of the RAS protein.
Rasonque is approved for adults with metastatic pancreatic adenocarcinoma who have already tried one round of treatment or cannot receive combination chemotherapy, and does not require a test to identify a specific RAS mutation first.
In the trial supporting approval, previously treated metastatic pancreatic adenocarcinoma patients taking the drug lived a median of 13.2 months versus 6.7 months on standard chemotherapy, according to the company.
Rasonque cut the risk of death by 60%, and patients went longer before disease progression and before pain and quality of life worsened.
Follow any of these and your For You feed starts watching them — no settings page required.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Regulator-validated but single-sourced and company-attributed
An FDA approval plus named-official and principal-investigator statements are strong external checkpoints, and the epidemiology is tied to a citable American Cancer Society report. Against that, the efficacy numbers are explicitly attributed to the company, there is no trial identifier, size, safety profile or confidence interval in the record, only one publisher covers the cluster, and the article contradicts itself on the review-timeline detail.
Launch-stage: priced, approved, 2,000 patients pre-launch, no uptake data
Real-world footprint is concrete but pre-commercial: an approval effective at publication, a set list price with a patient-support pathway, and more than 2,000 patients already treated through expanded access since May. No prescription volumes, payer coverage decisions, institutional formulary adoption or non-pancreatic use are documented, and the lung program has not reported.
Approved indication is well grounded; the platform extrapolation is not
The pancreatic-specific claims land close to the evidence: a real approval, a real price, a genuine survival gain that is actually 1.97x rather than a clean doubling. The overstatement sits in the extrapolation layer — 'works in the worst one, so it could work for everyone,' expectations of off-label use going wild, and a five-year 'post-cancer era' prediction — none of which has supporting data in the record, and all of which comes from a self-disclosed bullish shareholder while lung and colorectal trials remain unread.
Company-supplied data interpreted by a disclosed shareholder
Nearly every quantitative claim traces to Revolution Medicines: the survival medians, the 60% death-risk reduction, the 80%/3% late-stage statistics, the price and the copay program. The interpretive voice is an early RVMD shareholder who states his position and bullishness on the record, and the advocacy and investigator quotes come from parties with institutional stakes in the therapeutic area. Disclosure is present, which mitigates but does not remove the alignment of interests.
Core approval facts firm, surrounding analysis thin
Confidence is moderate: the approval, label, price and access-program facts are specific and checkable, and the arithmetic derivations follow directly from reported figures. But there is only one publisher, no independent trial documentation, no safety data, an internally contradicted timeline claim, and no adoption measurement after approval — enough to trust the event, not enough to trust the platform-scale conclusions.
science
Pancreatic cancer's undruggable target falls, and the median moves from 6.7 to 13.2 months3 distinct publishers
product
A blood-draw robot clears the FDA at 1m49s a stick. The missing number is per supervisor1 distinct publisher
science
Capricor's Duchenne vote is a verdict on design choices made years before the data1 distinct publisher
science
Focal prostate therapy is drifting outside the guideline that calls it experimental1 distinct publisher
Distinct publishers with included, body-backed reporting in this cluster.
1 article · August 26, 2026